# PDUFA dates October 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-10

> 35 FDA catalysts are dated in October 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in October 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 2027 | [Datopotamab deruxtecan (dato-dxd) primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT05489211 (Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05489211)) |
| October 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05801029)) |
| October 2027 | [Ibuzatrelvir primary completion](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 SARS-CoV-2 Infection | scheduled | "NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679140)) |
| October 2027 | [Budesonide/albuterol metered dose inhaler, mdi primary completion](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) | AZN | Asthma | scheduled | "NCT06471257 (A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06471257)) |
| October 2027 | [Azd2373-arm 1 primary completion](https://sec-api.dev/pdufa/azd2373-arm-1) | AZN | APOL1-Mediated Kidney Disease | scheduled | "NCT06824987 (Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824987)) |
| October 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668388)) |
| October 2027 | [Empasiprubart iv primary completion](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX |  | scheduled | "NCT07091630 (A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07091630)) |
| October 2027 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | SLE - Systemic Lupus Erythematosus | scheduled | "NCT07266090 (A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor Viatris Pharmaceuticals Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266090)) |
| October 2027 | [Gsk3772701 600 mg primary completion](https://sec-api.dev/pdufa/gsk3772701) | GSK | Malaria, Falciparum | scheduled | "NCT07545681 (A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545681)) |
| October 2027 | [ALXN2030 primary completion](https://sec-api.dev/pdufa/alxn2030) | AZN | Antibody-Mediated Rejection; Kidney Transplantation; Biopsy-proven Histologic Scores | scheduled | "NCT06744647 (Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744647)) |
| October 2027 | [Tarperprumig primary completion](https://sec-api.dev/pdufa/tarperprumig) | AZN | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | scheduled | "NCT07160608 (Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160608)) |
| October 2027 | [Laroprovstat primary completion](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolemia | scheduled | "NCT07930507 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07930507)) |
| October 2027 | [PF-08653944 primary completion](https://sec-api.dev/pdufa/pf-08653944) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07400653 (A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400653)) |
| October 2027 | [MK-7262 primary completion](https://sec-api.dev/pdufa/mk-7262) | MRK | Lipoprotein(a) | scheduled | "NCT07614984 (A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614984)) |
| October 2027 | [Bda mdi primary completion](https://sec-api.dev/pdufa/bda-mdi) | AZN | Asthma | scheduled | "NCT06307665 (Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307665)) |
| October 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06701903 (Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-14 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701903)) |
| October 2027 | [Puxitatug samrotecan primary completion](https://sec-api.dev/pdufa/puxitatug-samrotecan) | AZN | Endometrial Cancer; Malignant Solid Tumour | scheduled | "NCT07044336 (Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07044336)) |
| October 2027 | [Brenetafusp primary completion](https://sec-api.dev/pdufa/brenetafusp) | IMCR | Advanced Melanoma | scheduled | "NCT06112314 (IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-16 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112314)) |
| October 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04747613)) |
| October 2027 | [MK-8527 primary completion](https://sec-api.dev/pdufa/mk-8527) | MRK | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | scheduled | "NCT07071623 (A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07071623)) |
| October 2027 | [CTL019 primary completion](https://sec-api.dev/pdufa/ctl019) | NVS | B-Cell Acute Lymphoblastic Leukemia | scheduled | "NCT03876769 (Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03876769)) |
| October 2027 | [MK-8690 primary completion](https://sec-api.dev/pdufa/mk-8690) | MRK | Rheumatoid Arthritis | scheduled | "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07895524)) |
| October 2027 | [VOQUEZNA® (vonoprazan) primary completion](https://sec-api.dev/pdufa/vonoprazan) | PHAT | Symptomatic Non-erosive Gastroesophageal Reflux Disease | scheduled | "NCT07752407 (A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-20 (ESTIMATED); Lead Sponsor Phathom Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752407)) |
| October 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06824194 (Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824194)) |
| October 2027 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT06640049 (A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06640049)) |
| October 2027 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | scheduled | "NCT05923073 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05923073)) |
| October 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | scheduled | "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624204)) |
| October 2027 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Prurigo Nodularis | scheduled | "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293053)) |
| October 2027 | [VH4524184 primary completion](https://sec-api.dev/pdufa/vh4524184) | GSK | HIV Infections | scheduled | "NCT07202546 (A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202546)) |
| October 2027 | [MK-8690 primary completion](https://sec-api.dev/pdufa/mk-8690) | MRK | Colitis Ulcerative; Ulcerative Colitis | scheduled | "NCT07463183 (A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07463183)) |
| October 2027 | [MIMRYLO™ (rusfertide) primary completion](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07648030)) |
| October 2027 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Hypereosinophilic Syndrome | scheduled | "NCT05334368 (Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05334368)) |
| October 2027 | [SAR445399 primary completion](https://sec-api.dev/pdufa/sar445399) | SNY | Non-cystic Fibrosis Bronchiectasis | delayed | "NCT07547436 (A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07547436)) |
| October 2027 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer | scheduled | "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06095505)) |
| October 2027 | [Subcutaneous tislelizumab primary completion](https://sec-api.dev/pdufa/subcutaneous-tislelizumab) | ONC | Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | scheduled | "NCT07043400 (A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07043400)) |

Other months: https://sec-api.dev/fda-calendar/2027-09 , https://sec-api.dev/fda-calendar/2027-11. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates October 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-10

```bibtex
@misc{secapidev_fda_calendar_2027_10_20261116,
  title        = {PDUFA dates October 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-10}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_10_20261116","title":"PDUFA dates October 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-10","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
